Accretion Nutraveda Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Accretion Nutraveda Ltd is ₹ 267.5 as of 29 Apr 15:30 . The P/E Ratio of Accretion Nutraveda Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Accretion Nutraveda Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The Revenue of Accretion Nutraveda Ltd is ₹ 0 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Accretion Nutraveda Ltd is ₹ 0 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Accretion Nutraveda Ltd is ₹ 0 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Accretion Nutraveda Ltd changed from 0 % to 0 % over 8 quarters. This represents a CAGR of 0.0% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 8 quarters. This represents a CAGR of -100.00% .

About Accretion Nutraveda Ltd

Accretion Nutraveda Limited was initially incorporated as a Private Limited Company on March 16, 2021 and has subsequently, converted the status into a Public Limited Company vide Certificate of Incorporation issued by the Registrar of Companies, Central Processing Centre w.e.f.
May 2, 2025. The Company, established at Ahmedabad, is a healthcare-focused Contract Development and Manufacturing Organization (CDMO), offering specialized services to a diverse range of clients across the various industries.
It specialize in ayurvedic and nutraceutical products including Tablets, Capsules, Oral Liquids, Oral Powders, External Preparation and Oils.
Apart from these, it offer a diverse range of dosage forms, leveraging both Classical Ayurvedic principles and modern nutraceutical science. The products include Tablets, such as film-coated and chewable varieties, for applications in liver care, gynecological care, bone and joint health, and respiratory support.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Accretion Nutraveda Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Accretion Nutraveda Ltd or Sanofi India Ltd?

Market cap of Accretion Nutraveda Ltd is 193 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Accretion Nutraveda Ltd and Sanofi India Ltd?

The stock performance of Accretion Nutraveda Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Accretion Nutraveda Ltd and Sanofi India Ltd?

As of May 4, 2026, the Accretion Nutraveda Ltd stock price is INR ₹267.5. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Accretion Nutraveda Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Accretion Nutraveda Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.